---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-019052"
form_type: "8-K"
ticker: "MBIO"
cik: "0001680048"
company_name: "MUSTANG BIO, INC."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:44:36.179341+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Mustang Bio Q3 net loss narrows to $10.1M; cash drops to $10.3M, raises $4.4M post-quarter

## Summary
- Cash and equivalents $10.3M at Sep 30, down from $16.1M at Jun 30 and $76.7M at Dec 31, 2022.
- Net loss of $10.1M ($1.23/share) vs $19.0M ($2.42) in Q3 2022; R&D expenses fell to $9.5M.
- CFIUS review of uBriGene asset sale restarted; new 45-day review period began Nov 14, lease transfer delayed.
- MB-106 CAR-T showed 95% ORR in follicular lymphoma (n=20) and two complete responses in WM patients.
- FDA accepted IND for MB-109 (MB-101 + MB-108) for recurrent glioblastoma; Phase 1 trial planned.

## SEC filing metadata
- accession: 0001558370-23-019052
- form_type: 8-K
- ticker: MBIO
- cik: 0001680048
- company_name: MUSTANG BIO, INC.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680048/000155837023019052/0001558370-23-019052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680048/000155837023019052/tmb-20231114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-019052
- JSON: https://secwatch.observer/filing/0001558370-23-019052.json
- Plain text: https://secwatch.observer/filing/0001558370-23-019052.txt

## Key facts
- Earnings Releases
  MUSTANG BIO, INC. reported the third quarter ended September 30, 2023 results: net income Net loss attributable to common stockholders was $10.1 million, or $1.23 per share, for the third quarter of 2023, EPS $1.23 per share.
  - Period: the third quarter ended September 30, 2023
  - Net income: Net loss attributable to common stockholders was $10.1 million, or $1.23 per share, for the third quarter of 2023
  - EPS: $1.23 per share
  - Result: reported results
  source text: Mustang Bio, Inc. issued a press release to provide a corporate update and to announce its financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680048/000155837023019052/0001558370-23-019052-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.